HomeCompareMARUF vs JNJ

MARUF vs JNJ: Dividend Comparison 2026

MARUF yields 1.81% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MARUF wins by $41.79M in total portfolio value
10 years
MARUF
MARUF
● Live price
1.81%
Share price
$36.92
Annual div
$0.67
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.82M
Annual income
$37,798,884.64
Full MARUF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MARUF vs JNJ

📍 MARUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMARUFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MARUF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MARUF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MARUF
Annual income on $10K today (after 15% tax)
$153.67/yr
After 10yr DRIP, annual income (after tax)
$32,129,051.94/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MARUF beats the other by $32,125,065.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MARUF + JNJ for your $10,000?

MARUF: 50%JNJ: 50%
100% JNJ50/50100% MARUF
Portfolio after 10yr
$20.92M
Annual income
$18,901,787.02/yr
Blended yield
90.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MARUF
No analyst data
Altman Z
2.4
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MARUF buys
0
JNJ buys
0
No recent congressional trades found for MARUF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMARUFJNJ
Forward yield1.81%2.13%
Annual dividend / share$0.67$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$41.82M$30.3K
Annual income after 10y$37,798,884.64$4,689.40
Total dividends collected$41.48M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MARUF vs JNJ ($10,000, DRIP)

YearMARUF PortfolioMARUF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,062$361.58$10,592$272.30+$470.00MARUF
2$12,583$747.59$11,289$357.73+$1.3KMARUF
3$15,054$1,589.63$12,123$472.89+$2.9KMARUF
4$19,662$3,554.60$13,141$629.86+$6.5KMARUF
5$29,717$8,678.03$14,408$846.81+$15.3KMARUF
6$56,312$24,515.09$16,021$1,151.60+$40.3KMARUF
7$147,086$86,831.98$18,122$1,588.22+$129.0KMARUF
8$581,313$423,931.65$20,930$2,228.20+$560.4KMARUF
9$3,753,716$3,131,711.04$24,792$3,191.91+$3.73MMARUF
10$41,815,361$37,798,884.64$30,274$4,689.40+$41.79MMARUF

MARUF vs JNJ: Complete Analysis 2026

MARUFStock

Marubeni Corporation engages in various business activities worldwide. The company trades in grains, feed ingredients, compound feeds, foods, agricultural and fishery products, and fresh and processed meat; and apparel, footwear, lifestyle, and textile and industrial materials. It also provides agri-inputs, contracting services for fertilizer application and crop protection products, technical services, crop protection product formulations, fertilizers, and oilseeds; ICT and real estate services; petrochemicals and plastics, salts and chlor-alkalis, life science products, electronic materials, and inorganic mineral resources and chemicals; and wood chips, biomass fuels, pulp and waste papers, paper, paperboards, sanitary, and building and construction materials, as well as wood products. In addition, the company explores for, develops, and produces oil and gas; trades in, distributes, and markets petroleum and LPG; develops uranium, nuclear fuel cycle, iron ore, coal, and copper mines, as well as related equipment sales and services; smelts and refines aluminum and magnesium; trades in iron ore, coking coal, non-ferrous metals, ingots and related products, and steel products; and leases temporary steel construction materials. Further, it offers engineering, procurement, and construction, as well as operation and maintenance services for railway systems, water, industrial plants, and waste-to-energy power plants; energy and transportation infrastructure, and water business; and manages infrastructure funds, as well as engages in the power generation, renewable energy, power service and retail, natural gas, hydrogen, ammonia, municipal solid waste, and thermal energy storage businesses. Additionally, it owns, purchases, operates, leases, sells, and charters aerospace and ship products; and sells, trades in, leases, finances, and services construction and industrial machinery, and mobility products. The company was founded in 1858 and is headquartered in Tokyo, Japan.

Full MARUF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MARUF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MARUF vs SCHDMARUF vs JEPIMARUF vs OMARUF vs KOMARUF vs MAINMARUF vs ABBVMARUF vs MRKMARUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.